Develops targeted therapies for complement-mediated diseases using a proprietary LOGIC platform that integrates lead identification, optimization, in-vivo confirmation, and validation tools. By focusing on validated targets within the complement cascade, the company addresses the challenges of developing effective treatments for complex autoimmune and inflammatory conditions, with nine investigational assets in its pipeline.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective therapies for complement-mediated diseases is challenging due to the complexity of the complement system and the involvement of numerous proteins in autoimmune and inflammatory conditions. Traditional approaches struggle to achieve precise and durable immune modulation across various complement-driven diseases.
Solution
Kira Pharmaceuticals is developing targeted therapies for complement-mediated diseases, leveraging its proprietary LOGIC platform to overcome the challenges of complement drug development. The LOGIC platform integrates lead identification, optimization, in-vivo confirmation, and validation tools to design therapeutics that precisely modulate the complement cascade. This approach enables the development of first-in-class and best-in-class therapies with improved efficacy and safety profiles. Kira's pipeline includes nine novel complement assets focused on validated targets, addressing a range of autoimmune and inflammatory conditions across hematology, nephrology, neurology, dermatology, and ophthalmology. Their lead asset, KP104, is a dual-targeting complement inhibitor (anti-C5 & Factor H) currently in Phase 2 clinical trials, demonstrating long-term safety and efficacy as a monotherapy for Paroxysmal Nocturnal Hemoglobinuria (PNH).
Target Audience
The primary target audience includes patients suffering from complement-mediated diseases, as well as physicians and healthcare providers specializing in hematology, nephrology, neurology, dermatology, and ophthalmology.
Features
- LOGIC platform for rational drug design, integrating lead identification, optimization, in-vivo confirmation, and validation
- Pipeline of nine novel complement assets targeting validated points in the complement cascade
- KP104: a first-in-class dual-targeting complement inhibitor (anti-C5 & Factor H)
- Development of therapies for a broad range of complement-mediated diseases, including PNH, IgA Nephropathy (IgAN), and Complement 3 Glomerulopathy (C3G)
- Focus on both intravascular and extravascular hemolysis control in PNH
- Clinical programs designed to address unmet medical needs in complement-driven diseases